Super T2-FLAIR mismatch sign: a prognostic imaging biomarker for non-enhancing astrocytoma, IDH-mutant
Journal of Neuro-Oncology · 2024
DOI: 10.1007/s11060-024-04758-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neuro-Oncology, 2024. Verfasst von Iori Ozono und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Ja…. Hauptthemen laut MEDLINE: Isocitrate Dehydrogenase, Astrocytoma, Brain Neoplasms, Magnetic Resonance Imaging. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hiroshima University.
Abstract (Originalsprache)
Purpose
The T2-FLAIR mismatch sign is a highly specific diagnostic imaging biomarker for astrocytoma, IDH-mutant. However, a definitive prognostic imaging biomarker has yet to be identified. This study investigated imaging prognostic markers, specifically analyzing T2-weighted and FLAIR images of this tumor.
Methods
We retrospectively analyzed 31 cases of non-enhancing astrocytoma, IDH-mutant treated at our institution, and 30 cases from The Cancer Genome Atlas (TCGA)/The Cancer Imaging Archive (TCIA). We defined “super T2-FLAIR mismatch sign” as having a significantly strong low signal comparable to cerebrospinal fluid at non-cystic lesions rather than just a pale FLAIR low-signal tumor lesion as in conventional T2-FLAIR mismatch sign. Cysts were defined as having a round or oval shape and were excluded from the criteria for the super T2-FLAIR mismatch sign. We evaluated the presence or absence of the T2-FLAIR mismatch sign and super T2-FLAIR mismatch sign using preoperative MRI and analyzed the progression-free survival (PFS) and overall survival (OS) by log-rank test.
Results
The T2-FLAIR mismatch sign was present in 17 cases (55%) in our institution and 9 cases (30%) within the TCGA-LGG dataset without any correlation with PFS or OS. However, the super T2-FLAIR mismatch sign was detected in 8 cases (26%) at our institution and 13 cases (43%) in the TCGA-LGG dataset. At our institution, patients displaying the super T2-FLAIR mismatch sign showed significantly extended PFS (122.7 vs. 35.9 months, p = 0.0491) and OS (not reached vs. 116.7 months, p = 0.0232). Similarly, in the TCGA-LGG dataset, those with the super T2-FLAIR mismatch sign exhibited notably longer OS (not reached vs. 44.0 months, p = 0.0177).
Conclusion
The super T2-FLAIR mismatch is a promising prognostic imaging biomarker for non-enhancing astrocytoma, IDH-mutant.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.
- Department of Pathology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
- Department of Neurosurgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan. fyama@hiroshima-u.ac.jp.
Förderung
- Hiroshima University
Zitieren
APA
Ozono, I., Onishi, S., Yonezawa, U., Taguchi, A., Khairunnisa, N. I., Amatya, V. J., Yamasaki, F., Takeshima, Y., & Horie, N. (2024). Super T2-FLAIR mismatch sign: a prognostic imaging biomarker for non-enhancing astrocytoma, IDH-mutant. Journal of Neuro-Oncology. https://doi.org/10.1007/s11060-024-04758-4
Vancouver
Ozono I, Onishi S, Yonezawa U, Taguchi A, Khairunnisa NI, Amatya VJ, et al. Super T2-FLAIR mismatch sign: a prognostic imaging biomarker for non-enhancing astrocytoma, IDH-mutant. Journal of Neuro-Oncology. 2024. doi:10.1007/s11060-024-04758-4
BibTeX
@article{Ozono2024,
author = {Ozono, Iori and Onishi, Shumpei and Yonezawa, Ushio and Taguchi, Akira and Khairunnisa, Novita Ikbar and Amatya, Vishwa Jeet and Yamasaki, Fumiyuki and Takeshima, Yukio and Horie, Nobutaka},
title = {Super T2-FLAIR mismatch sign: a prognostic imaging biomarker for non-enhancing astrocytoma, IDH-mutant},
journal = {Journal of Neuro-Oncology},
year = {2024},
doi = {10.1007/s11060-024-04758-4}
}
EUVIMED